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Organic chemicals that absorb UVA
(400–315 nm) or UVB (315–280 nm) radi-
ation are added in concentrations up to 10%
to sunscreen products for skin protection.
Some of the compounds are also included in
other cosmetics such as beauty creams, lip-
sticks, skin lotions, hair sprays, hair dyes,
shampoos, and bubble baths for product sta-
bility and durability. 
Because of growing public concern
about skin damage by UV light, the use of
UV screens is increasing, even though the
benefit with respect to prevention of
melanoma remains controversial (1,2). Like
other cosmetics such as musk fragrances
(3,4), these chemicals are highly lipophilic
and therefore can be expected to bioaccumu-
late in the environment. In 1991 and 1993,
six different UV screens were identified in
fish of the Meerfelder Maar lake (Eifel,
Germany) at total concentrations of 2 mg/kg
lipid in perch (summer 1991) and 0.5
mg/kg lipid in roach (1993) (5). Both fish
species were contaminated with sunscreens,
polychlorinated biphenyls and DDT at com-
parable levels. From these results it appeared
that UV screens are relevant environmental
contaminants (5). 
Humans can be exposed to UV screens
by dermal absorption (6–9) or through the
food chain. The UV screen benzophenone-3
(Bp-3) and its metabolite 2,4-dihydroxyben-
zophenone have been detected in human
urine from 4 hr after application of commer-
cially available sunscreen products to the
skin (7,10). Bp-3 has also been found to be
readily absorbed from the gastrointestinal
tract (11). Evidence for bioaccumulation in
humans stems from analyses of human milk
(12). In five out of six samples of human
milk, Bp-3 and/or octyl methoxycinnamate
were present in detectable amounts.
At present, the toxicologic classification
of UV screens is rather heterogenous; they
are classiﬁed as over-the-counter drugs in the
United States, cosmetic ingredients in the
European Union, and either cosmetics or
quasi-drug products in Japan (13). Acute and
subchronic systemic toxicity of these com-
pounds is considered to be rather low
(7,14,15), although some problems have
arisen with photoallergic reactions (16). No
values of acceptable daily intake or maximal
tolerated intake of UV screens have been
defined. However, the bioaccumulation
potential of these lipophilic chemicals does
not appear to have been considered in earlier
published toxicologic long-term studies. The
evidence of bioaccumulation in wildlife and
humans raises the possibility of long-term
exposure, including effects on reproduction
and ontogeny. As a consequence, these com-
pounds should be tested for endocrine activity.
We analyzed six frequently used UVA-
or UVB-absorbing UV screens for estrogenic
activity in vitro in MCF-7 breast cancer cells
and in vivo in the immature rat uterotrophic
assay. Estrogenic activity was demonstrated
for ﬁve out of six compounds in vitro and for
three out of six compounds in vivo by the
oral route. The orally most active compound
also increased uterine weight following der-
mal application.
Materials and Methods
Chemicals
The UV screens Bp-3 (2-hydroxy-4-methoxy-
benzophenone, oxybenzone, Eusolex 4360);
butyl methoxydibenzoylmethane (B-MDM,
Eusolex 9020); homosalate (HMS, 2-hydrox-
ybenzoic acid-3,3,5-trimethylcyclohexyl ester,
Eusolex HMS); 3-(4-methylbenzylidene)
camphor (4-MBC, Eusolex 6300); octyl-
dimethyl-p-aminobenzoic acid (OD-PABA,
Eusolex 6007); and octyl-methoxycinnamate
(OMC, Eusolex 2292) were purchased from
Merck (Dietikon, Switzerland). 17β -Estradiol
(E2) and 17α -ethinylestradiol were obtained
from Calbiochem (Lucerne, Switzerland), and
ICI 182,780 (Astra-Zeneca) was purchased
from  ANAWA (Dübendorf, Switzerland).
In Vitro Studies on MCF-7 Cells
Cell line. MCF-7 human breast cancer cells
(MCF7-Bos, originally from the Michigan
Cancer Foundation, Detroit, MI, USA) were
kindly provided by A. Soto (Tufts University,
Boston, MA, USA). Cells were frozen every
10 passages. In the present experimental
series, we used samples from frozen stock for a
maximum of 6–13 passages. Mycoplasma sta-
tus, which was regularly checked by the
Institute of Virology of the Veterinary Faculty
of the University of Zurich, was negative.
Cells were cultured in Dulbecco’s modified
Eagle Medium (DME) supplemented with
5% fetal bovine serum (FBS; Gibco, Life
Technologies, Basel, Switzerland) in 5%
CO2/95% air at 37°C under saturated
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Ultraviolet (UV) screens are increasingly used as a result of growing concern about UV radiation
and skin cancer; they are also added to cosmetics and other products for light stability. Recent data
on bioaccumulation in wildlife and humans point to a need for in-depth analyses of systemic toxi-
cology, in particular with respect to reproduction and ontogeny. We examined six frequently used
UVA and UVB screens for estrogenicity in vitro and in vivo. In MCF-7 breast cancer cells, ﬁve out
of six chemicals, that is, benzophenone-3 (Bp-3), homosalate (HMS), 4-methyl-benzylidene cam-
phor (4-MBC), octyl-methoxycinnamate (OMC), and octyl-dimethyl-PABA (OD-PABA),
increased cell proliferation with median effective concentrations (EC50) values between 1.56 and
3.73 µM, whereas butyl-methoxydibenzoylmethane (B-MDM) was inactive. Further evidence for
estrogenic activity was the induction of pS2 protein in MCF-7 cells and the blockade of the prolif-
erative effect of 4-MBC by the estrogen antagonist ICI 182,780. In the uterotrophic assay using
immature Long-Evans rats that received the chemicals for 4 days in powdered feed, uterine weight
was dose-dependently increased by 4-MBC (ED50 309mg/kg/day), OMC (ED50 935 mg/kg/day),
and weakly by Bp-3 (active at 1,525 mg/kg/day). Three compounds were inactive by the oral route
in the doses tested. Dermal application of 4-MBC to immature hairless (hr/hr) rats also increased
uterine weight at concentrations of 5 and 7.5% in olive oil. Our ﬁndings indicate that UV screens
should be tested for endocrine activity, in view of possible long-term effects in humans and
wildlife. Key words: benzophenone-3, estrogenic activity, MCF-7 cell proliferation, 4-methylben-
zylidene camphor, octylmethoxycinnamate, pS2 protein, rat, uterotrophic assay, UV screens.
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were removed from the serum by charcoal
dextran treatment [steroid hormone-free FBS
(CD-FBS)] (17). 
E-SCREEN. The E-SCREEN was per-
formed according to Soto and co-workers
(17,18). Brieﬂy, MCF-7 cells were trypsinized,
mechanically dissociated, and plated into 24-
well plates (Costar; INTEGRA Biosciences,
Wallisellen, Switzerland) at an initial concen-
tration of 40,000 cells/well. Cells were
allowed to attach in the seeding medium
(DME supplemented with 5% FBS) for 24
hr. The seeding medium was then aspirated
and replaced by the experimental medium
containing phenol red-free DME with 10%
CD-FBS. Cells were incubated with test com-
pound (final concentrations 10–4–10–7 M),
E2 as positive control (10–8–10–13 M), or
chemical-free medium (control) (Table 1).
For each concentration, 4 wells per plate were
used. The number of independent in vitro
experiments is given in Table 1 and in ﬁgures
representing in vitro data. Each experiment
was accompanied by a positive control (E2).
Concentrations of stock solutions in absolute
ethanol were 2 ×  10–3 M for E2 and 10–2 M
for UV screens; final concentrations of
ethanol in culture medium were between
1.0% and 0.001% (v/v) with test com-
pounds, and were ≤ 0.0005% (v/v) with E2.
No difference in the cell proliferation rate was
observed in control experiments with chemi-
cal-free medium or medium with 1.0%
ethanol. Therefore, we used chemical-free
medium as a control. We tested antagonism
by the pure antiestrogen ICI 182,780 (19) in
MCF–7 cells exposed for 6 days to E2 (10
pM ) or to 4–MBC (10 µM) in the presence
or absence of 1, 10, or 100 nM ICI 182,780.
Measurement of cell proliferation.
Experiments were terminated after 6 days of
incubation by removing the media from the
wells. Cells were fixed with 10% trichloro-
acetic acid, washed with phosphate-buffered
saline, and stained with 1% sulforhodamine
blue (0.4% in 1% acetic acid, 1 mL/well) for
15 min at room temperature. Stained cells
were dissolved in TRIS buffer (pH 10.6), and
optical density (OD) was measured in a
Anthos Labtec 2000 spectrophotometer
(Anthos Labtec Instruments, Salzbury,
Austria) at 492 nm. OD values were con-
verted into cell numbers by a standard curve.
Experimental readings were in the linear
range of the standard curve (Figure 1).
pS2 protein assay. MCF-7 cells were
incubated 72 hr with UV screens at 5, 10,
and 50 µM; data are shown for 10 µM
(except HMS 50 µM). E2 (10 pM) served as
a positive control. Culture media were har-
vested and centrifuged to avoid floating of
detached cells. Samples were kept at –80ºC
until the radioimmunoassay for pS2 protein
was performed according to the protocol of
the manufacturer (ELSA - PS2; CIS Bio
International, Gif-sur-Yvette, France).
Media were analyzed in duplicate. 
In Vivo Studies
Uterotrophic assay. Animal experiments
were performed in accordance with the Swiss
Federal Act on Animal Protection and the
Swiss Animal Protection Ordinance under
permit 190/98 of the Veterinary Office of
the State of Zurich. We tested estrogenic in
vivo activity of UV screens using the rat
uterotrophic assay (20,21). Long-Evans rats
were bred in our laboratory under controlled
light and dark cycle (lights on from 0200 to
1600 hr) and temperature (22°C ± 1°C),
with standard diet (chow 3430; Provimi
Kliba AG, Kaiseraugst, Switzerland) and
water ad libitum. All experiments were per-
formed on offspring of time-pregnant rats.
Receptive females were mated with a male
between 1600 and 1900 hr. Sperm-positive
females were housed in groups of two to
three and separated 1 day before parturi-
tion.We defined the stage 24 hr after onset
of the 3-hr mating period as gestational day
(GD) 1 and the day of birth as postnatal day
(PN) 1 (GD 23).
Peroral administration of test chemicals.
From PN 16, the pups and their dam were
habituated to powdered chow (chow 3430,
Provimi Kliba), which continued after wean-
ing at PN 20. Beginning on PN 21, female
pups received chow 3430 containing one of
several concentrations of test compound for
4 days, until 1200 hr on PN 25. For each
experiment, chemicals were dissolved either
in acetone or in 99% ethanol and added to
powdered chow 3430. The mixture was pre-
pared at least 48 hr before the experiment to
allow for complete evaporation of the sol-
vent. Evaporation was assisted by continuous
stirring. We used ethinylestradiol (0.3–10
µg/kg) as a positive control. Vehicle controls
received normal chow 3430. To limit the
number of experimental animals, we adjusted
the size of the various treatment groups
according to statistical needs. We used the
minumum group sample size of the three UV
screens that we determined were inactive. 
To avoid stress to the immature pups,
we housed the animals in groups of four to
six. We recorded body weight at the begin-
ning and at the end of the treatment period.
Animals from different litters were randomly
assigned to the various treatment groups to
give similar mean body weights to the vari-
ous treatment groups at the onset of treat-
ment, with no more than 15% deviation of
individual animals from the mean. Mean
body weights of experimental groups were in
the same range as that of the controls (initial
weight 38.0 ± 4.5 g, ﬁnal weight 48.8 ± 3.8
g). We calculated the mean body weight of
the 4-day treatment period for each animal.
Food consumption of the group of four to
six animals was measured for the 4-day
period. The mean daily dose was calculated
from the average amount of chemical con-
sumed per animal (ingested powdered chow
per animal × concentration of test com-
pound in chow per mean body weight of a
given animal). The advantage of using the
average values of consumption is that the
animals were not disturbed. The consistency
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Table 1. Effect of UV screens and E2 on MCF-7 cell
proliferation in vitro.
Compound/
concentration (M) Cells/well
E2
0 44,501 ± 5,079 (13)
1 × 10–13 61,093 ± 12,200 (4)
5 × 10–13 61,563 ± 2,090 (6)
1 × 10–12 333,970 ± 51,026 (11)*
1 × 10–11 743,296 ± 88,655 (11)#
1 × 10–10 677,115 ± 91,301 (10)#
1 × 10–9 655,969 ± 77,928 (10)#
1 × 10–8 623,608 ± 72,292 (11)#
4-MBC 
0 49,028 ± 15,924 (6)
1 × 10–7 132,292 ± 33,478 (6)
1 × 10–6 147,396 ± 46,267 (6)
5 × 10–6 583,299 ± 51,178 (6)#
1 × 10–5 661,597 ± 66,740 (6)#
5 × 10–5 330,157 ± 68,896 (6)**
OMC
0 55,504 ± 13,373 (6)
1 × 10–7 147,033 ± 25,657 (6)
1 × 10–6 229,688 ± 65,150 (6)
5 × 10–6 594,809 ± 74,438 (6)#
1 × 10–5 566,945 ± 88,253 (6)#
5 × 10–5 215,985 ± 58,542 (6)
Bp-3
0 40,292 ± 2,422 (5)
1 × 10–7 99,605 ± 28,489 (5)
1 × 10–6 71,438 ± 29,796 (5)
5 × 10–6 448,750 ± 78,557 (5)#
1 × 10–5 704,750 ± 53,108 (5)#
5 × 10–5 680,354 ± 63,914 (5)#
HMS
0 96,292 ± 15,512 (5)
1 × 10–7 155,771 ± 20,505 (5)
1 × 10–6 279,833 ± 22,404 (5)**
5 × 10–6 573,042 ± 50,308 (5)#
1 × 10–5 652,917 ± 35,943 (5)#
5 × 10–5 586,479 ± 14,416 (5) #
OD-PABA
0 47,726 ± 14,068 (6)
1 × 10–7 113,229 ± 24,761 (6)
1 × 10–6 76,719 ± 6,740 (6)
5 × 10–6 290,181 ± 59,554 (6)**
1 × 10–5 435,827 ± 35,692 (6)#
5 × 10–5 326,021 ± 63,239 (6)#
B-MDM
0 28,125 ± 5,381 (5)
1 × 10–7 99,104 ± 35,589 (5)
1 × 10–6 29,833 ± 6,559 (5)
5 × 10–6 73,250 ± 46,864 (5)
1 × 10–5 120,846 ± 79,925 (5)
5 × 10–5 54,297 ± 19,109 (5)
Values shown are mean ± SEM (number of independent
experiments). 
* p < 0.05, ** p < 0.01, # p < 0.001 (ANOVA plus Bonferroni
pairwise comparisons) as compared to control.of the condition is indicated by an SD/mean
ratio of uterine weights of 5.6% in controls
and 9.8% in treated groups.
At the end of the treatment period, pups
were decapitated under light ether anesthe-
sia.The uterus was excised, trimmed free of
fat and connective tissues, and blotted with
sterile gauze to remove adherent fluid.The
uterus was cut just above the junction
between the cervix and vagina and at the top
of the uterine horns. It was then weighed
(wet weight) and either frozen in liquid
nitrogen or fixed in buffered 4% formalde-
hyde for further analysis.
Dermal application of test chemicals. We
studied possible effects of dermal application
of UV screens in immature females of the
Rat Nu (hairless) strain (Ico: OFA hr/hr).
Parent animals were obtained from IFFA
CREDO (Labresle, France) and kept under
the same conditions as the Long-Evans rat
colony (see above). One hr+/hr+ male was
caged with three adult hr+/hr+ females.
Pregnant dams were identified by weight
gain, and the date of parturition (PN 1) was
registered. Because of difﬁculties of the lac-
tating hr+/hr+ dams to produce sufficient
milk, the dam was replaced on PN 2 by a
lactating Long-Evans dam. Pups were
weaned at PN 20.
Female rat pups were treated on 6 con-
secutive days, from PN 21 to PN 26. 4-MBC
[2.5%, 5.0%, 7.5% (w/w) in olive oil] or
olive oil (vehicle control) was applied twice
daily at an interval of 3–4 hr. At 30°C ambi-
ent temperature, the animal was gently held
by the neck and immersed up to its shoulders
into a glass beaker containing olive oil with
4-MBC or pure olive oil for 15 sec. The pup
was then transferred into a plastic box (one
animal per box), where it remained on a
paper towel for 30 min. During the 30-min
period, an additional amount of the solution
was applied twice onto the back of the ani-
mal with a soft brush. After 30 min, the skin
appeared dry; the animal was transferred
onto a clean paper towel to remove remain-
ing solution and then returned to its home
cage. We used separate plastic boxes for 4-
MBC-treated pups and controls. The animals
were continuously observed; they did not lick
their skin, but remained in a quiet position.
On PN 27, pups were weighed and decapi-
tated under light ether anesthesia. The uterus
was removed and weighed as described
above. The treatment group was unknown to
the person dissecting the uterus.
In the absence of toxicokinetic in vivo
data, it is not possible to exactly determine
the dose of 4-MBC taken up by dermal appli-
cation. However, we determined the amount
of olive oil applied during one treatment by
weighing the animal before and after each
manipulation. The average amount of oil
retained after 15 sec immersion was 1.35 ±
0.13 g, and the additional amount applied by
the brush was 1.4 ± 0.08 g. Thus, the total
amount of oil was 2.75 g/treatment or 5.5
g/day, yielding total amounts of 4-MBC
applied to the skin per day of 137.5, 275, and
412.5 mg for 2.5, 5.0, and 7.5% 4-MBC
concentrations, respectively. According to in
vitro data (8), the penetration of 4-MBC
through hairless rat skin is 0.6% from oily
gels or 0.4% from a water in oil (W/O) emul-
sion. Assuming 0.6% penetration, the dose
absorbed from a 5% 4-MBC solution in oil
can be tentatively calculated as 37 mg/kg/day
based on mean body weight of the 5% group. 
Data Analysis
In vitro studies. We calculated cell counts per
well from optical density as described above.
In every experiment, we analyzed each con-
centration in quadruplicate. From these val-
ues, we calculated the mean cell count of a
given concentration of chemical or of chemi-
cal-free medium for each experiment. Cell
counts from different independent experi-
ments were compared using analysis of vari-
ance (ANOVA) followed by Bonferroni
pairwise comparisons (SYSTAT software;
SYSTAT Intelligent Software, Evanston, IL,
USA). The proliferative effect (PE) of a com-
pound was defined as (maximal mean cell
count obtained with the test chemical)/(mean
cell count in the chemical-free medium), the
relative proliferative effect (RPE) in relation
to that of E2 as (PE of test compound
–1)/(PE of E2 – 1) × 100 (17). For compari-
son with uterotrophic data, we expressed the
increase in cell number as percentage of E2
[(cell number with test compound – con-
trol)/(cell number with E2 – control) × 100].
We calculated the median effective concentra-
tion (EC50) values from the ascending part of
the concentration–response curve using
Graph Pad Prism2 software (Graph Pad
Software, Inc., San Diego, CA, USA). For
pS2 protein, treated groups and the chemical-
free medium group were compared by
ANOVA followed by Bonferroni pairwise
comparisons (SYSTAT).
In Vivo Studies
Uterine weights of individual animals from
different dose groups and vehicle controls
were compared by ANOVA followed by
Bonferroni pairwise comparisons. We calcu-
lated ED50 values using Prism2.
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Figure 1. Representative standard curve of MCF-7
cell density (cells/mL) versus optical density (1%
sulforhodamine blue staining). Linear regression
with 95% confidence limits (r 2 = 0.9065). Circles
represent mean values of 16 replicates.
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Table 2. Comparison of in vitro and in vivo activity of UV screens and steroidal estrogens.
MCF-7 cell proliferation Uterotrophic effect in immature rats
Maximal cell  Increase of  Maximal 
count increase  uterine weight  weight increase
Compound PEa RPEb (% of E2)c EC50 over controld (% of EE2)e ED50
E2 16.70 100 100 1.22 pM
EE2 4.08 100 0.818 µg/kg/day
Bp-3 17.49 105.0 95.09 3.73 µM 1.23 7.60 1,000–1,500 mg/kg/day
4-MBC 13.49 79.54 87.66 3.02 µM 2.09 35.51 309 mg/kg/day
OMC 10.72 61.90 77.18 2.37 µM 1.68 22.21 934 mg/kg/day
OD-PABA 9.13 51.77 55.54 2.63 µM 1.04 1.15 Inactive
HMS 6.78 36.81 79.65 1.56 µM 1.12 3.79 Inactive
B-MDM 4.30 21.01 13.27 Inactive 1.06 2.01 Inactive
EE2, ethinylestradiol. 
aProliferative effect over control; PE = (maximal cell count of experimental group)/(cell count of control). bMaximal proliferative effect (% of E2); RPE = (PE of experimental group – 1)/(PE
of estradiol – 1) × 100. c(Cell count of experimental group – cell count of control)/(cell count of estradiol – cell count of control) × 100. d(Uterine weight of experimental group)/(uterine
weight of control). eMaximal weight increase (% of ethinylestradiol) = (uterine weight of experimental group – uterine weight of control)/(uterine weight of ethinylestradiol – uterine
weight of control) × 100.Results
Effect of UV Screens on MCF-7 Cells
in Vitro
MCF-7 cell proliferation. Cell proliferation
was dose-dependently increased by all UV
screens tested except for B-MDM, with a
bell-shaped dose–response curve (Tables 1
and 2, Figure 2). The effective concentration
range (1–50 µM) and the maximum effect
concentration (at around 10 µM) was similar
for the various compounds. In vitro EC50 val-
ues of UV screens range between 1.56 µM
(HMS) and 3.73 µM (Bp-3) (Table 2).
According to their maximum effects on cell
proliferation in relation to E2, 4-MBC,
OMC, OD-PABA, and HMS acted as partial
agonists, whereas the maximum activity of
Bp-3 reached the level of E2. The proliferative
effects of 4-MBC and the positive control E2
were completely blocked by the pure estrogen
receptor antagonist ICI 182,780 (Figure 3).
pS2 protein. Secretion of the estrogen-
regulated protein pS2 into the culture
medium was significantly increased by 4-
MBC, HMS, and Bp-3 (Figure 4). Levels
were also above control after incubation with
OMC and OD-PABA, but the difference
was not significant; B-MDM was clearly
negative. At the concentration tested, 4-
MBC induced the greatest response (43.9%
of E2). The correlation between the increase
in proliferation and in pS2 secretion at the
concentration used for pS2 protein induc-
tion was low (r2 = 0.6046, not signiﬁcant).
Effect of UV Screens on the
Immature Rat Uterus in Vivo
Peroral administration. After administration
in powdered feed for 4 days, three of the ﬁve
chemicals active in vitro and the positive con-
trol ethinylestradiol elicited dose-dependent
increases in uterine weight of immature Long-
Evans rats (Table 3, Figure 2). The rank order
of potency, 4-MBC > OMC > Bp-3, differed
from the one observed in vitro; 4-MBC exhib-
ited a signiﬁcant increase in uterine weight at a
dose of 119 mg/kg/day and an ED50 of 309
mg/kg/day (Tables 2,3). Two of the com-
pounds with in vitro activity, HMS and OD-
PABA, as well as B-MDM, were inactive in
vivo at the doses tested. Mean body weights of
the various treatment groups were similar
(data not shown) and in the range of the vehi-
cle control group (mean ± SD of 38.0 ± 4.5 g
at PN 21 and 48.8 ± 3.8 g at PN25).
Dermal application of 4-MBC.
Following dermal application of 4-MBC in
olive oil twice daily for 6 days, immature rats
of the hr/hr (hairless) strain exhibited a dose-
dependent increase in uterine weight, with a
signiﬁcant increase above control induced by
5% and 7.5% 4-MBC (Figure 5). The mean
uterine weight of the 5% 4-MBC group was
also signiﬁcantly higher than that of the 2.5
or 7.5% groups, yielding a bell-shaped
dose–response curve. The control uterine
weight of this strain appeared to be slightly
lower than that of Long-Evans rats, even
though the animals were 2 days older. Mean
body weights (± SD) of the various groups
were similar at the beginning (control, 34.78
± 3.15; 2.5% 4-MBC, 32.54 ± 1.40; 5% 4-
MBC, 34.44 ± 4.10; 7.5% 4-MBC, 34.51 ±
1.92) and at the end of the treatment period
(control, 52.52 ± 7.41; 2.5% 4-MBC, 43.63
± 0.81; 5% 4-MBC, 55.99 ± 5.38; 7.5% 4-
MBC, 51.11 ± 5.07). 
Discussion
The present study demonstrates in vitro and
in vivo estrogenic activity for a number of UV
screens with different chemical structures.
The compounds tested are frequently used in
sunscreens and cosmetics and have the poten-
tial for bioaccumulation.
In the in vitro system, ﬁve out of the six
UV screens tested displayed signiﬁcant dose-
dependent estrogenic activity on MCF-7
cells. Bp-3 was most active on cell prolifera-
tion, followed by 4-MBC, HMS, OMC, and
OD-PABA, whereas B-MDM was inactive.
With maximum effects on MCF-7 cell pro-
liferation at 5–10 µM and EC50 values
between 1.5 and 3.7 µM (Table 2), the estro-
genic activity of the ﬁve UV screens is in the
range of other industrial chemicals identiﬁed
as environmental estrogens (17,22). The
strain of MCF-7 cells used displayed good
sensitivity to E2, with a maximum prolifera-
tion rate at 10 pM, comparable to previously
published data (17). This enabled good dis-
crimination between test chemicals. It cannot
be determined whether the effects of the UV
screens were caused by the parent com-
pounds and/or by possible metabolites
because MCF-7 cells express constitutive and
inducible cytochrome P450 enzymes (23). 
Complete blockage of the proliferative
effect of 4-MBC by the pure estrogen recep-
tor antagonist ICI 182,780 (19) indicates an
estrogen receptor-mediated effect. The estro-
genic activity of these chemicals is further
demonstrated by the induction of the estro-
gen-regulated pS2 protein (24). The correla-
tion between the effects of the six chemicals
on cell proliferation and pS2 protein
(expressed as percentage of E2) was low (r2 =
0.6046, not signiﬁcant); however, the same
compounds (4-MBC, Bp-3, and HMS) were
most active on proliferation as well as pS2
protein induction, and B-MDM was clearly
inactive on both parameters. It should be
noted that the effect on pS2 protein was only
analyzed for one concentration of test chemi-
cals in the range of the maximum proliferative
effect. The dose–response relationship and,
hence, the maximum effective dose may be
different for the two parameters.
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Figure 3. Antagonism of the proliferative effect of
4-MBC (10 µM) or E2 (10 pM) on MCF-7 cells by
increasing concentrations of the pure estrogen
receptor antagonist ICI 182,780. Controls received
chemical-free medium. ICI 182,780 alone was 100
nM. Values shown are mean ± SEM of four inde-
pendent experiments. 
*p < 0.001 (ANOVA followed by Bonferroni pairwise com-
parisons) as compared to all other experimental groups
(control, ICI 182,780 alone, and E2 or 4-MBC plus ICI
182,780 at all concentrations). 
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Figure 2. Dose–response relationship of estrogenic activity of different UV screens. (A) In vitro effect of
UV screens on MCF-7 cell proliferation (cell number/well) as a percentage of the maximum effect of E2.
(B) Effect of oral UV screens on immature rat uterine weight as a percentage of the maximum effect of
ethinylestradiol (EE2). 
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4-MBCThree UV screens, 4-MBC, OMC, and
Bp-3, were active by the oral route in an
acute mammalian in vivo model for estro-
genicity (21), eliciting dose-dependent
increases of uterine weight in immature rats.
Differences between individual UV screens
were more pronounced than in vitro. 4-MBC
was most active, with a signiﬁcant increase in
uterine weight at 119 mg/kg/day and an
ED50 of 309 mg/kg/day; it also had the
greatest maximal effect (Table 2). In contrast,
Bp-3 displayed only weak activity in vivo.
This compound has recently been reported
to be inactive in the uterotrophic assay (25).
The dose level used was also ineffective in our
investigation; thus, the two data sets are in
agreement. The in vitro (proliferation) and in
vivo dose–response curves of 4-MBC and
OMC suggest that they are partial agonists.
Bp-3 is difﬁcult to judge because it reached
the level of the full agonist, E2, in vitro,
whereas the in vivo dose–response curve is
incomplete.
Weak binding to estrogen receptors has
been reported for unsubstituted benzophe-
none (26). One of the main metabolites of
Bp-3, 2,4-dihydroxybenzophenone, binds to
estrogen receptors with micromolar afﬁnity,
in contrast to its parent compound (27). This
metabolite was detected in human urine after
dermal application of a commercial sun-
screen product (10). O-dealkylation also
appears to be the major metabolic pathway of
Bp-3 in rats (28). However, the relative roles
of parent compounds and metabolites for in
vivo estrogenic activities of the various UV
screens remain to be clariﬁed. 
A comparison of in vitro and in vivo data
indicates that the in vitro assay was useful for
identifying estrogenic activity, but was of lim-
ited predictive value for the mammalian in
vivo situation. Although all three chemicals
that exhibited in vivo activity were strongly
active in vitro, two compounds with high or
moderate in vitro activity, HMS and OD-
PABA, were completely inactive in the
uterotrophic assay at the doses tested. The
rank orders of activity also differed between
in vitro and in vivo experiments. This may
have resulted from pharmacodynamic and/or
pharmacokinetic differences. A precise quan-
titative comparison of in vitro and in vivo
effects is not possible because different tissues
served as end points and different estrogens
were used as positive controls. The differences
between in vitro and in vivo data support the
need for in vivo testing of chemicals after
identiﬁcation of endocrine activity in vitro.
The investigated chemicals are diverse in
structure, but they share a common use as
UVA or UVB screens and they have poten-
tial for bioaccumulation. Four of the UV
screens with estrogenic activity, 4-MBC, Bp-
3, HMS, and OMC, have been detected in
fish (5), and so far two compounds, Bp-3
and OMC, have been detected in human
milk (12). The total concentration of estro-
genic UV screens in ﬁsh, where a larger data
set is available, ranged between 1.6 µM and
7.8 µM in fat, or between 0.02 and 0.2 µM
in whole ﬁsh (roach and perch, respectively).
UV screens thus may contribute to the total
body burden of endocrine active compounds
in wildlife and humans. 
The effective dose range of oral 4-MBC,
OMC, and Bp-3 in the rat uterotrophic assay
(119 mg/kg/day for 4-MBC to 1,500
mg/kg/day for Bp-3) compares with daily oral
doses of bisphenol A (400 mg/kg) (29),
methoxychlor (100–500 mg/kg), nonylphe-
nol (190–1,000 mg/kg), and o,p´-DDT
(1,000 mg/kg) (21,30) that increase rodent
uterine weight. Uterine epidermal growth fac-
tor receptor was induced by 500 mg/kg/day
methoxychlor (31). In one study on bisphe-
nol A, Gould et al. (32) were unable to detect
changes in uterine weight, but they reported
an increase in peroxidase activity at 100
mg/kg/day and increased progesterone recep-
tor levels at lower doses. These doses cannot
be compared with actual exposure levels, as it
is generally agreed that the acute high-dose
rodent model cannot serve as a basis for risk
assessment, but rather for identiﬁcation of in
vivo activity. Thus, bisphenol A has been
found to disturb developmental processes at
doses that are several orders of magnitude
lower (2–50 µg/kg) (33,34). 
As UV screens, the chemicals tested in
this study present two different toxicologic
aspects: On one hand, they may play an eco-
toxicologic role in wildlife and humans, prob-
ably resulting mainly from intake via the food
chain. On the other hand, they may also be
transdermally active in humans when they are
used as sunscreens. We observed an increase
in uterine weight after dermal application of
Articles • Estrogenicity of UV screens
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Figure 4. Effect of UV screens 4-MBC (10 µM), HMS (50 µM), Bp3 (10 µM), OMC (10 µM), OD-PABA (10
µM), B-MDM (10 µM), and E2 (10 pM) on pS2 protein secretion by MCF-7 cells. Bars indicate mean pS2
protein concentration in culture medium (pg/ml) ± SEM; numbers inside the bars indicate the number of
independent experiments). 
*p < 0.05, **p < 0.001 (ANOVA followed by Bonferroni pairwise comparisons) as compared to controls that received
chemical-free medium. 
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Figure 5. Effect of dermal application of 4-MBC
(2.5, 5.0, or 7.5 % in olive oil, twice daily for 6 days)
on uterine weight of immature hairless (hr+/hr+)
rats. Controls received vehicle (olive oil). Bars
indicate mean ± SD; numbers inside the bars indi-
cate the number of animals. 
a5% 4-MBC different from 2.5%, p < 0.005; different from
7.5%, p < 0.001 #p < 0.001, ‡‡p < 0.025 as compared to
controls (ANOVA followed by Bonferroni pairwise com-
parisons). 
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n = 11
n = 4
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n = 84-MBC in olive oil to immature hairless rats
at concentrations allowed in sunscreen prod-
ucts. The dose–response curve of uterine
weight was bell-shaped, suggesting more
complex interactions. With 5% 4-MBC, the
increase (159% of control) corresponded to
the increase (154% of control) produced by
an oral dose of 337 mg/kg/day, which is
close to the oral ED50. 4-MBC exhibits sig-
niﬁcant penetration through skin of hairless
rats from a 6% solution in either a W/O
emulsion or oily gels (8). BP-3 is also der-
mally absorbed in rats (35). Evidence for
absorption by human skin has been pre-
sented for 4-MBC, Bp-3, and OD-PABA
(6,7,9,10); 4-MBC also penetrates a foliox-
ane membrane, a model for human skin (8).
Skin penetration may vary between com-
pounds, as indicated by lower penetration of
OMC as compared to Bp-3 (9,36), and
appears to be inﬂuenced by the formulation
(8,36). Such kinetic differences may be of
importance from a toxicologic point of view,
but present knowledge is too incomplete to
provide a picture of the general human
exposure to UV screens. 
Conclusions
Our investigation revealed that several fre-
quently used UV screens possess estrogenic
activity in vitro and in vivo, in the range of
other known xenoestrogens. With the excep-
tion of some benzophenones, these chemi-
cals do not appear to have been considered
as potential environmental endocrine disrup-
tors (37). Considering the widespread use of
UV screens, we suggest that toxicokinetics,
in particular skin penetration, and systemic
toxicology of these chemicals should be
investigated more extensively. In view of
possible long-term effects, screening for
endocrine activity seems important. From
our data and from observations in other
fields (see above), it appears that there is a
need to reconsider the potential benefits of
extensive UV screen use both from a medical
and an ecologic perspective.
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Table 3. Effect of oral UV screens and ethinylestra-
diol on uterine weight of immature rats.
Dose Uterine weight (mg)
Ethinylestradiol (µg/kg/day)
0.085 29.15  ± 3.59  (6) 
0.342 37.02  ± 1.05  (6)##
0.780 61.82  ± 5.00  (5)##
0.856 72.80  ± 5.77  (5)##
1.648 102.86  ± 13.09  (5)##
8.631 100.95  ± 3.28  (6)##
4-MBC (mg/kg/day)
66 27.25 ± 1.72 (10)
119 32.43 ± 3.61 (13)‡
211 35.24 ± 5.84 (19)##
337 38.78 ± 6.36 (18)##
402 45.22 ± 8.23 (9)##
1,980 52.80 ± 11.8 (4)##
OMC (mg/kg/day)
268 24.95  ± 2.50  (10)
522 26.81 ± 1.64 (13) 
1,035 35.46  ± 8.74  (10)##
1,518 39.59  ± 7.58  (7)##
2,667 42.48  ± 1.25  (5)##
Bp-3 (mg/kg/day)
611 26.84 ± 1.87 (5)
937 26.94 ± 2.26 (9)
1,525 31.14 ± 3.13 (5)##
HMS (mg/kg/day)
491 28.18 ± 1.64 (6)
892 23.36 ± 0.96 (5)
OD-PABA (mg/kg/day)
596 26.05 ± 0.95 (4)
761 24.75 ± 1.29 (6)
1,419 26.13 ± 3.10 (6)
B-MDM (mg/kg/day)
421 26.80 ± 1.08 (6)
636 26.05 ± 0.97 (6)
Vehicle control
0 25.24 ± 1.41 (28)
Values shown are mean ± SD (number of rats).
##p < 0.0001, ‡p < 0.002 (ANOVA plus Bonferroni pairwise
comparisons) as compared to controls. 